Skip to main content
Clinical Trials/NCT00633516
NCT00633516
Completed
Not Applicable

A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters

University of California, Irvine2 sites in 1 country37 target enrollmentStarted: July 2008Last updated:
ConditionsSkin Cancer

Overview

Phase
Not Applicable
Status
Completed
Enrollment
37
Locations
2
Primary Endpoint
Measure atypical moles and melanoma

Overview

Brief Summary

The incidence of malignant melanoma has increased dramatically in recent decades. In 1930, the lifetime risk of an individual in the United States developing melanoma was 1 in 1,500. This has been exponentially increasing over the years with the risk estimated to be 1 in 75 in 2000 . According to the American Cancer Society, approximately 59,580 new cases of melanoma will be diagnosed in the United States in 2005 and about 7,770 people are expected to die of the disease.

Detailed Description

The researcher ucan use special imaging devices to obtain information about a typical mole and melanoma and use this information to determine the different between malignant and benign melanized lesions. The imaging devices are, Modified Two Layer Diffuse Optical Spectroscopy,multi-spectral imaging, and Spatially Modulated Quantitative Spectroscopy can use to measure atypical moles and melanoma and correlate the results of the biopsy tissue histology.

The imaging devices can quantify melanin, oxy and deoxy hemoglobin concentration, water, lipid and reduced scattering coefficients and can compare results to histopathologic. Atypical moles and melanoma have a different optical profile based on physiological parameters compared to benign nevus.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • 18 years or older.
  • Have atypical mole/s and melanoma

Exclusion Criteria

  • Age less than 18 years old.
  • have NO atypical mole/s and melanoma

Outcomes

Primary Outcomes

Measure atypical moles and melanoma

Time Frame: 4 weeks

Optical Spectroscopy imaging of atypical moles and melanoma to correlate results from the results of the biopsy tissue histology

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Beckman Laser Institute and Medical Center

David Hsiang, M.D., Division of Surgical Oncology

University of California, Irvine

Study Sites (2)

Loading locations...

Similar Trials